Medtronic ($MDT) is looking to get its neurostimulation devices indicated for patients with failed back surgery syndrome, kicking off a global trial that will test to see whether the tech beats out drugs in patients with resulting lower back pain. Medtronic will enroll up to 300 patients at 30 centers in the U.S., Canada and Europe, and it's the first trial of its size to test surgical-lead-based neurostimulation on predominant lower back pain, the company said. The trial will also study the economic and quality of life factors related to the treatment, according to Medtronic. More